Navigation Links
BioNeutral Group Receives $400,000 in Equity Financing
Date:12/27/2011

MORRISTOWN, N.J., Dec. 27, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTCBB: BONU), a specialty life science technology-based company, today announced that it has received $400,000 in connection with the Preferred Stock Purchase Agreement (the "Agreement") with Vinfluence Pty Ltd ("Vinfluence"), New South Wales, Australia.  Pursuant to the Agreement, BioNeutral Group, Inc. received $200,000 from the initial closing and a second funding of $200,000, both from the sale of Series C Convertible Preferred Stock.  As per the Agreement the company will receive monthly funding of $200,000 for each of the next three months, for a total funding of $1M.   Further details of the Preferred Stock Purchase Agreement can be found in our SEC filings.

Frank Battafarano, Chairman of the Board of BioNeutral Group, said, "We are pleased to have completed the closing with Vinfluence providing us with $400,000 in working capital.  Our recent financing has provided us with the opportunity to develop and further enhance our relationships with both new and existing key vendors and suppliers. We look forward to our relationship with Vinfluence in 2012 providing us with access to additional equity-based financing helping us to further commercialize our products."

About BioNeutral Group, Inc.

Headquartered in Morristown New Jersey with lab facilities at the New Jersey Institute of Technology in Newark New Jersey, BioNeutral Group, Inc. is a specialty technology-based life-science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores.  BioNeutral's products, Ygiene® and Ogiene®, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States and has previously been approved for sale in Germany and it is also permitted to be sold in the UK, France and Sweden. Auto Neutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutral.com.

Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393  

Follow us on Twitter: http://twitter.com/bioneutralgroup  

Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.

 


 

 


'/>"/>
SOURCE BioNeutral Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioNeutral Starts Commercial Deployment of Its Ygiene 206 Sterilant and Ogiene Products Within Port Authority Facilities Using T.U.C.S. Cleaning Services
2. BioNeutral to Premier its EPA-Approved Ygiene® 206 Hospital-Grade Disinfectant at the Annual 2011 APIC Conference, While Community Health of South Florida Begins Product Review
3. BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
4. BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board
5. BioNeutral Enters into Global Sales and Distribution Agreement with Raymond Associates to Expand Market for Military-Grade Ygiene(TM)
6. BioNeutral Group Secures Three Initial Trial Orders for its Ogiene™ Odor Neutralizer & Multi-Purpose Cleaner Product Line
7. BioNeutral Group to Receive Economic Development Incentives
8. Kentucky Hospital Association Solutions Group Outlines Next Steps for BioNeutral Partnership
9. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Proven To Be Completely Inert to Steel In Independent Corrosion Testing
10. BioNeutral Groups CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM In Focus Radio Show Hosted by Dr. Dan Miller
11. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... 2017 , ... AxioMed president, Jake Lubinski, describes the AxioMed ... deformed, which is identical to how the human discs work to distribute force. ... to its natural state along a hysteresis curve, exactly like a healthy human ...
(Date:3/23/2017)... 2017  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), ... for solid tumor cancers, today announced that yesterday ... announced last Friday, March 17, 2017. ... securities totaling 28,843,692 shares, comprised of 18,843,692 common ... of Class C Warrants pre-funded at the closing ...
(Date:3/23/2017)... -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical ... reported financial results for the quarter and year ... update on the company,s clinical development efforts and ... pleased to report that last year was a ... Krammer. "We achieved key clinical milestones and attracted ...
(Date:3/23/2017)... , March 23, 2017 NetworkNewsWire ... ... death, putting significant strain on health care systems, in terms ... diagnoses rises, so too does the development of innovative and ... side effects. Among the many types of cancer treatments, a ...
Breaking Biology Technology:
(Date:3/9/2017)... MOUNTAIN VIEW, Calif. , March 9, 2017 /PRNewswire/ ... 23andMe , the leading personal genetics company, are ... can now provide customers with personalized nutrition plans that ... biometrics, but also genetic markers impacting how their body ... personalized food decision support platform uses biometrics such as ...
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
Breaking Biology News(10 mins):